OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases.
Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools.
OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.
Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools.
OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.
Location: Belgium, Wallonia, Cosselies
Employees: 51-200
Phone: +32 71 18 35 00
Total raised: $29.17M
Founded date: 2012
Investors 3
| Date | Name | Website |
| - | Inventures | inventures... |
| - | Le Groupe ... | sriw.be |
| - | SFPIM | sfpim.be |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.02.2020 | Series B | $20.58M | - |
| 04.09.2016 | - | $8.59M | - |
Mentions in press and media 4
| Date | Title | Description |
| 17.02.2020 | Internacional: OncoDNA cierra una ronda Serie B de €19M, acuden Vesalius Biocapital, Swisscanto Invest, SFPI y otros | 17/02/2020 Nota de prensa INTERNACIONAL: ONCODNA CIERRA UNA RONDA SERIE B DE €19 MILLONES, ACUDEN VESALIUS BIOCAPITAL, SWISSCANTO INVEST, SFPI Y OTROS. Se suman a su accionariado el fondo de capital riesgo europeo Vesalius Biocapital III... |
| 14.02.2020 | OncoDNA Closes €19M Series B Funding | OncoDNA, a Gosselies, Belgium-based healthcare technology company focusedd on precision medicine, raised €19m ($20m) in Series B equity financing. The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank wi... |
| 14.02.2020 | Belgian OncoDNA closes €19 million Series B to expand its oncology software | Gosselies-based OncoDNA, the healthtech making precision medicine a reality, today announced that it has completed a €19 million Series B equity financing. The new funding will support rapid international growth, accelerate software develop... |
| 04.09.2016 | OncoDNA Closes €7.7M Equity Financing Round | OncoDNA SA, a Gosselies, Belgium-based precision medicine company, closed a €7.7m equity financing round. Backers included historical shareholders IPG/bio.be, Invest4OncoDNA, Sambrinvest, and Vinsovier as well as new investors Sofinim, an a... |